Literature DB >> 18931391

Development of antiviral agents for enteroviruses.

Tzu-Chun Chen1, Kuo-Feng Weng, Shih-Cheng Chang, Jing-Yi Lin, Peng-Nien Huang, Shin-Ru Shih.   

Abstract

Enteroviruses (EVs) are common human pathogens that are associated with numerous disease symptoms in many organ systems of the body. Although EV infections commonly cause mild or non-symptomatic illness, some of them are associated with severe diseases such as CNS complications. The current absence of effective vaccines for most viral infection and no available antiviral drugs for the treatment of EVs highlight the urgency and significance of developing antiviral agents. Several key steps in the viral life cycle are potential targets for blocking viral replication. This article reviews recent studies of antiviral developments for EVs based on various molecular targets that interrupt viral attachment, viral translation, polyprotein processing and RNA replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931391     DOI: 10.1093/jac/dkn424

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection.

Authors:  Minetaro Arita; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 2.  Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.

Authors:  S Aswathyraj; G Arunkumar; E K Alidjinou; D Hober
Journal:  Med Microbiol Immunol       Date:  2016-07-12       Impact factor: 3.402

3.  Labdane-type diterpenoids from Vitex limonifolia and their antivirus activities.

Authors:  Ninh Khac Ban; Nguyen Thi Kim Thoa; Tran My Linh; Do Thi Trang; Phan Van Kiem; Nguyen Xuan Nhiem; Bui Huu Tai; Chau Van Minh; Jae-Hyoung Song; Hyun-Jeong Ko; Seung Hyun Kim
Journal:  J Nat Med       Date:  2017-09-15       Impact factor: 2.343

Review 4.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

Review 5.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

6.  Cellular Proteins Act as Bridge Between 5' and 3' Ends of the Coxsackievirus B3 Mediating Genome Circularization During RNA Translation.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Curr Microbiol       Date:  2015-07-03       Impact factor: 2.188

7.  Chemical components from the twigs of Caesalpinia latisiliqua and their antiviral activity.

Authors:  Mira Oh; SeonJu Park; Jae-Hyoung Song; Hyun-Jeong Ko; Seung Hyun Kim
Journal:  J Nat Med       Date:  2019-06-26       Impact factor: 2.343

8.  Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71.

Authors:  Tzu-Chun Chen; Hwan-You Chang; Pei-Fen Lin; Jyh-Haur Chern; John Tsu-An Hsu; Chu-Yi Chang; Shin-Ru Shih
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

9.  Molecular Analysis of RNA-RNA Interactions between 5' and 3' Untranslated Regions during the Initiation of Translation of a Cardiovirulent and a Live-Attenuated Coxsackievirus B3 Strains.

Authors:  Amira Souii; Jawhar Gharbi; Manel Ben M'hadheb-Gharbi
Journal:  Int J Mol Sci       Date:  2013-02-25       Impact factor: 5.923

10.  Ribosomal Initiation Complex Assembly within the Wild-Strain of Coxsackievirus B3 and Live-Attenuated Sabin3-like IRESes during the Initiation of Translation.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Bruno Sargueil; Audrey Brossard; Nathalie Chamond; Mahjoub Aouni; Jawhar Gharbi
Journal:  Int J Mol Sci       Date:  2013-02-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.